

Drug	Mechanism (CYP3A4, P-gp)	Evidence type	Primary source(s) (PMID/Link)	Measured GFJ effect – Cmax (x)	Measured GFJ effect – AUC (x)	Estimated effect if drug 2h BEFORE grapefruit – Cmax	Estimated effect if drug 2h BEFORE grapefruit – AUC	Estimated effect if drug 2h AFTER grapefruit – Cmax	Estimated effect if drug 2h AFTER grapefruit – AUC	Notes
Vortioxetine	Primarily CYP2D6; not P-gp	Mechanism not CYP3A4/P-gp – GFJ effect unlikely								No primary evidence of grapefruit interaction; major...
Duloxetine	CYP1A2/2D6; not P-gp	Mechanism not CYP3A4/P-gp – GFJ effect unlikely								No primary evidence of grapefruit interaction; primary...
Lercanidipine	CYP3A4 substrate	Label contraindication; no quantitative human...	SmPC/PI (e.g., Teva/HPRA)			≈1.0	≈1.0	↑ (qualitative)	↑ (qualitative)	Labels state GFJ markedly increases exposure; avoid...
Paracetamol (Acetaminophen)	UGT; minor CYP; not P-gp	Mechanism not CYP3A4/P-gp – GFJ effect...								No reliable human data for grapefruit; animal data...
Domperidone	CYP3A4 + P-gp substrate	Label contraindication; inhibitor PK data	Health Canada PM; ketoconazole ↑AUC/Cmax 3–10×			≈1.0	≈1.0	↑ (qualitative)	↑ (qualitative)	No direct domperidone+GFJ PK; mechanism supports...
Zopiclone	CYP3A4 (major) + CYP2C8	Inhibitor data (erythromycin/itraconazole)	Monographs, BJCP/DMD papers			≈1.0	≈1.0	≈1.2–1.5	≈1.2–1.5	No human GFJ trial; modest ↑ expected if GFJ precedes dose.
Baclofen	Renal elimination; not CYP3A4/P-gp	Mechanism not CYP3A4/P-gp – GFJ effect unlikely								No mechanism for grapefruit interaction.
Modafinil	Moderate CYP3A4 inducer; minor substrate	Mechanism (3A4 induction); no GFJ data	Reviews (BJP/CPT)			≈1.0	≈1.0	≈1.0	≈1.0	GFJ unlikely to meaningfully change modafinil PK.
Nebivolol	CYP2D6; not P-gp	Mechanism not CYP3A4/P-gp – GFJ effect unlikely								No mechanism for grapefruit interaction.
Metamizole (Dipyrone)	Multiple pathways; not primarily CYP3A4	Mechanism not CYP3A4/P-gp – GFJ effect unlikely								No mechanism for grapefruit interaction.
Pramipexole	Renal elimination; not CYP3A4/P-gp	Mechanism not CYP3A4/P-gp – GFJ effect unlikely								No mechanism for grapefruit interaction.

Drug	Mechanism (CYP3A4, P-gp)	Evidence type	Primary source(s) (PMID/Link)	Measured GFJ effect – Cmax (x)	Measured GFJ effect – AUC (x)	Estimated effect if drug 2h BEFORE grapefruit – Cmax	Estimated effect if drug 2h BEFORE grapefruit – AUC	Estimated effect if drug 2h AFTER grapefruit – Cmax	Estimated effect if drug 2h AFTER grapefruit – AUC	Notes
Rabeprazole	Non-enzymatic + CYP2C19; not P-gp	Mechanism not CYP3A4/P-gp – GFJ effect unlikely								No mechanism for grapefruit interaction.
Sirolimus (Rapamycin)	CYP3A4 + P-gp substrate	Human GFJ PK study	Cohen 2012 Clin Cancer Res (~3.5× AUC)		≈3.5	≈1.0	≈1.0	↑ (likely large)	≈3.0–4.0	GFJ used as PK booster; large AUC increase; Cmax not...
Prucalopride	Weak P-gp substrate; minimal CYP3A4	Human DDI (ketoconazole)	EMA SmPC: ketoconazole ↑~40%		≈1.4 (with keto)	≈1.0	≈1.0	≈1.0–1.1	≈1.0–1.1	GFJ expected ≤ ketoconazole effect; small change.
Sildenafil	CYP3A4 substrate	Randomized crossover GFJ PK	Jetter 2002 CPT: AUC ↑~23%, Cmax ~same	≈1.0	≈1.23	≈1.0	≈1.0–1.05	≈1.0	≈1.2–1.3	GFJ delayed Tmax; Cmax unchanged; modest AUC ↑.
Tizanidine (Sirdalud)	CYP1A2; not P-gp	Mechanism not CYP3A4/P-gp – GFJ effect unlikely								No mechanism for grapefruit interaction.
Zolpidem	CYP3A4 (major) + CYP2C19/1A2 minor	Inhibitor DDI (voriconazole)	Saari 2007 BJCP: Cmax 1.23×; AUC 1.48×			≈1.0	≈1.0	≈1.1–1.3	≈1.2–1.5	GFJ before dose likely modest ↑ based on CYP3A4...
Lorazepam	UGT glucuronidation; not CYP3A4/P-gp	Mechanism not CYP3A4/P-gp – GFJ effect unlikely								No mechanism for grapefruit interaction.
Levothyroxine	Absorptive interactions; not CYP3A4/P-gp	Mechanism not CYP3A4/P-gp – GFJ effect unlikely								GFJ may slightly delay absorption; minimal impact.
Tramadol	CYP2D6 + CYP3A4 metabolism	Mechanistic PK; no GFJ human study	Coller 2012; Haage 2018			≈1.0	≈1.0	≈1.0–1.2	≈1.0–1.2	Overall exposure effect uncertain without direct GFJ...
Daridorexant	CYP3A4 substrate (major); likely P-gp substrate	Human modulator (diltiazem) + label/IB...	FDA Label 2022 (NDA 214985); diltiazem ↑Cmax~1.4× AUC~2.4×;...			≈1.0	≈1.0	≈1.4–1.6	≈2.5–4.0	Avoid grapefruit; no direct GFJ PK published.